Long-acting HIV prevention and birth control study
Part of Immune system & allergy, Infections clinical trials.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman at least 18 years old, less than 14 days after giving birth
- Be HIV-negative (or willing to test for HIV) and not currently on HIV treatment
- Plan to stay in the Gaborone, Molepolole, or Mochudi area for at least 18 months for follow-up visits
- Be willing to get blood drawn every 4 weeks during the study period
- Not be taking certain medications (like seizure or TB medications) that interfere with the study drugs
- Have a healthy weight (BMI under 35) and normal liver and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This study follows people taking a new long-acting HIV prevention injection called LA CAB (cabotegravir). Researchers want to understand how well it works, how people use it, and what side effects occur in real-world NHS clinics.
This study looks at how well HIV treatment (ART) and a hormonal birth control method (DMPA shot or implant) work together, using small blood samples. It may help ensure safer, more effective HIV care and contraception for young women.
This study tests a long-acting injectable HIV prevention medicine called cabotegravir in newborn babies who were exposed to HIV. The goal is to see if it can help protect them from getting HIV.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.